IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q90022

Maki IWAHASHI, et al.

Appln. No.: Unknown

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: September 06, 2005

Examiner: Unknown

For: INDOLE DERIVATIVE COMPOUNDS AND PHARMACEUTICAL AGENTS

COMPRISING THE COMPOUND AS AN ACTIVE INGREDIENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

A copy of an International Search Report in a counterpart application is submitted herewith. The references cited in the International Search Report are submitted on CD-ROM.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

10/548089

INFORMATION DISCLOSURE STATEMENT U.S. Appln. No.: Based on PCT/JP04/002813

JC05 Rec'd PCT/PTO 06 SEP 2005

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents (International Search Report for PCT/JP04/002813 ated April 27, 2004), together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

Registration No. 32,197

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: September 6, 2005

JC05 Rec'd PCT/PTO 0 6 SEP 2005

MODIFIED PTO/SB/08 A & B (06-03)

plete if Known

Unknown

Substitute for Form 1449 A & B/PTO

Sheet



INFORMATION DISCLOSURE STATEME

(use as mar

1

NT BY APPLICANT	Filing Date	September 06, 2005
	First Named Inventor	Maki IWAHASHI
ny sheets as necessary)	Art Unit	Unknown
	Examiner Name	Unknown
of 1	Attorney Docket Number	Q90022

Application Number

Confirmation Number

U.S. PATENT DOCUMENTS					
Examiner Initials*		Document N	Document Number		
	Cite No.1	Number	Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Docum
		US			
-		US			
		US			
		US			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	. Cite	Foreign Patent Document			Publication Date	Name of Patentee or	-
	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		WO	03/022813	A1	03-03-2003	Ono Pharmaceutical Co., Ltd.	
		WO	01/66520	A1	09-13-2001	Ono Pharmaceutical Co., Ltd.	
		EP	1 170 594	A2	01-09-2002	Pfizer Products Inc.	
		GB	997,638		03-20-1962		
			*				
		-		- 			
				_	-		
	_			- -			
				+			
		<u> </u>	<u> </u>				

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation
		International Search Report dated April 27, 2004	

l -	
Examiner Signature	Date Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.